Incorporating Individual and Collective Ethics into Phase I Cancer Trial Designs
Article first published online: 19 AUG 2010
© 2010, The International Biometric Society
Volume 67, Issue 2, pages 596–603, June 2011
How to Cite
Bartroff, J. and Leung Lai, T. (2011), Incorporating Individual and Collective Ethics into Phase I Cancer Trial Designs. Biometrics, 67: 596–603. doi: 10.1111/j.1541-0420.2010.01471.x
- Issue published online: 20 JUN 2011
- Article first published online: 19 AUG 2010
- Received May 2009. Revised May 2010. Accepted May 2010.
- Cancer trials;
- Logistic regression;
- Markov decision problem;
- Phase I
Summary A general framework is proposed for Bayesian model based designs of Phase I cancer trials, in which a general criterion for coherence (Cheung, 2005, Biometrika 92, 863–873) of a design is also developed. This framework can incorporate both “individual” and “collective” ethics into the design of the trial. We propose a new design that minimizes a risk function composed of two terms, with one representing the individual risk of the current dose and the other representing the collective risk. The performance of this design, which is measured in terms of the accuracy of the estimated target dose at the end of the trial, the toxicity and overdose rates, and certain loss functions reflecting the individual and collective ethics, is studied and compared with existing Bayesian model based designs and is shown to have better performance than existing designs.